PolyPid Announces FDA Acceptance Of Its New Drug Application With A Priority Review For D-PLEX100 For The Prevention Of Surgical Site Infections In Patients Undergoing Abdominal Colorectal Surgery; PDUFA Action Date Is November 28

PolyPid Q2 EPS $(0.35) Beats $(0.38) Estimate

PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.38) by 7.89 percent. This is a 55.13 percent increase over losses of $(0.78) per share from the same

PolyPid shares are trading higher after the company announced that the FDA accepted its New Drug Application and granted it a Priority Review for D-PLEX100

HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $13 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates PolyPid (NASDAQ:PYPD) with a Buy and maintains $13 price target.